Registry for patients with lung disease from premature birth

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The Preterm Lung Patient Registry is an observational initiative aimed at collecting data on individuals who have experienced neonatal lung disease, particularly bronchopulmonary disease (BPD). Established in 2008, this registry seeks to identify epidemiologic and genetic factors that influence the condition in former preterm infants. By analyzing phenotype and genotype information, the registry helps clinicians and researchers improve care, monitor health trends, and guide clinical research related to BPD. The data collected will inform quality improvement initiatives and address various healthcare issues affecting this vulnerable population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Former preterm infant

Where it's running

• Boston Children's Hospital
  Boston, Massachusetts, United States Recruiting

Study contacts

• Study coordinator: Lystra Hayden, MD, MMSc
• Email: Lystra.Hayden@childrens.harvard.edu

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Screening for bronchopulmonary cancer in a structured network

  This study is testing a new way to screen for lung cancer using special scans in a network of health centers to see if it helps catch the disease early.

  Recruiting at 4 sites Institut Curie · Bobigny and 8 other locations · NCT06439901

• Lung Ultrasound Score to predict BPD in very preterm babies

  This study tests whether lung ultrasound scores in the first two weeks of life can predict which extremely preterm babies will develop bronchopulmonary dysplasia.

  Recruiting at 4 sites Azienda USL Reggio Emilia - IRCCS · Modena and 3 other locations · NCT07633184

• Caffeine in pregnancy: how the mother and baby handle it during delivery

  This study tests how caffeine is processed in pregnant people and how much reaches the baby when given shortly before delivery.

  Recruiting Phase 1 Indiana University · Indianapolis, Indiana · NCT07570121

• IVIG for bronchopulmonary dysplasia in infants born at 28 weeks or earlier

  This trial will try intravenous immunoglobulin (IVIG) given over five days to see if it helps very preterm infants (≤28 weeks) who show early signs of bronchopulmonary dysplasia.

  Recruiting Phase 2 International Peace Maternity and Child Health Hospital · Shanghai · NCT07561125

• High-energy DHA/ARA-enriched human milk in the first 2 weeks to lower lung problems in extremely preterm babies

  This trial tests whether giving DHA/ARA-enriched, fortified human milk in the first 14 days after birth helps extremely preterm infants breathe easier and have better lung function.

  Recruiting Phase 1/2 University of Alabama at Birmingham · Birmingham, Alabama · NCT07307612

• Reduced versus higher daily fluids to prevent bronchopulmonary dysplasia in very preterm babies

  This tests whether giving smaller daily fluid volumes from day 8 of life (about 135 mL/kg/day) instead of larger volumes (about 165 mL/kg/day) lowers the chance of developing BPD or dying before 36 weeks in babies born before 30 weeks.

  Recruiting at 9 sites University Children's Hospital Basel · Aarau and 8 other locations · NCT06954142

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.